<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772547</url>
  </required_header>
  <id_info>
    <org_study_id>VIGAB-STAT IIa</org_study_id>
    <secondary_id>IRB202003076</secondary_id>
    <secondary_id>OCR40379</secondary_id>
    <nct_id>NCT04772547</nct_id>
  </id_info>
  <brief_title>VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa</brief_title>
  <acronym>VIGAB-STAT</acronym>
  <official_title>VIGABatrin in Post-anoxic STATus Epilepticus - Phase IIa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial of a single loading dose of vigabatrin in post-anoxic status&#xD;
      epilepticus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot trial aims to demonstrate the feasibility of enteral administration of a single&#xD;
      load of vigabatrin within targeted 48 hours of post-anoxic status epilepticus onset in&#xD;
      unconscious survivors of cardiac arrest undergoing targeted temperature management. The load&#xD;
      of VGB is in addition to the load of a commonly used intravenous second-line therapy given at&#xD;
      the discretion of the treating neurologist. Serial blood tests will be obtained, including&#xD;
      vigabatrin levels, taurine levels, neuron specific enolase, light chain neurofilament, and&#xD;
      glial fibrillary acidic protein. In survivors that regain consciousness and survive to follow&#xD;
      up, 6 months visual field perimetry will be obtained.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>pilot feasibility trial of pharmacokinetics of drug absorption</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participants are unconscious, thus, inherently blinded to the intervention. All the endpoints are objective and will be assessed by a blinded investigator to the timing of vigabatrin administration.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Vigabatrin levels</measure>
    <time_frame>up to day 7</time_frame>
    <description>Blood levels of vigabatrin using high-performance liquid chromatography. Detectable levels of vigabatrin in 80% of subjects by 3 hours and 100% of subjects by 12 hours will be considered the threshold for adequate absorption.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Status Epilepticus, Electrographic</condition>
  <condition>Coma</condition>
  <arm_group>
    <arm_group_label>Open label</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4500 mg of vigabatrin administered enterally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vigabatrin Only Product</intervention_name>
    <description>enteral medication administration, serial blood draws, and outcome assessment</description>
    <arm_group_label>Open label</arm_group_label>
    <other_name>sabril, vigabatrone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥ 18 years&#xD;
&#xD;
          -  non-traumatic cardiac arrest (regardless of non-perfusing rhythm, etiology, or&#xD;
             location of arrest) in whom the decision to employ targeted temperature monitoring and&#xD;
             to treat unequivocal electrographic status epilepticus (as defined by the American&#xD;
             Clinical Neurophysiology Society: having generalized spike/sharp-wave discharges ≥ 3Hz&#xD;
             or any evolving pattern reaching &gt; 4Hz, lasting ≥ 10 minutes, or comprising &gt; 50% of&#xD;
             any hour of recording) has been made&#xD;
&#xD;
          -  requiring anesthetic infusion for any reason,&#xD;
&#xD;
          -  established enteral access within 48h of post-anoxic status epilepticus onset.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior history of generalized epilepsy&#xD;
&#xD;
          -  status epilepticus onset preceding initiation of electroencephalography monitoring&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carolina B Maciel, MD, MSCR</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jessica Spana</last_name>
    <phone>3522735554</phone>
    <email>Jessica.Spana@neurology.ufl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie Segura</last_name>
    <phone>(352) 733-2412</phone>
    <email>Julie.Segura@neurology.ufl.edu</email>
  </overall_contact_backup>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 23, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>post-anoxic status epilepticus, cardiac arrest, nonconvulsive status epilepticus, coma, vigabatrin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Status Epilepticus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vigabatrin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

